Introduction {#S1}
============

Olfactory receptors (ORs) are G-protein coupled receptors (GPCR), which are mainly expressed in the cilia of the olfactory epithelium ([@B3]). Binding of a ligand odorant stimulates signal transduction pathways to transduce odor information to the brain ([@B10]). It has also been reported that ORs are ectopically expressed in different extra-nasal tissues, including liver, kidney, adipose, intestine and muscle tissues ([@B32]). Thus, the functionalities of ectopic ORs have been investigated in the last decade. For instance, MOR23 activation stimulates the cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) activity in skeletal muscle tissue. This pathway regulates the migration and adhesion of skeletal muscle cells, thereby contributing to wound healing and tissue repair ([@B17]). A few ORs regulate lipid metabolism and obesity. We previously reported that OR1A1 and its mouse homolog, Olfr43, regulate lipid metabolism in the liver. OR1A1/Olfr43 stimulated by (-)-carvone reduced hepatic steatosis through regulating the PKA-cAMP-response element binding protein (CREB)- hairy and enhancer of split-1 signaling axis ([@B61], [@B62]). The results from microarray analysis showed that Olfr544 is highly expressed in both mouse liver and white adipose tissue, and activation of Olfr544 stimulates fatty acid oxidation in hepatocytes, lipolysis and thermogenesis in white and brown adipose tissues ([@B60]), respectively. Olfr544 is also expressed in pancreatic α-cells to stimulate glucagon secretion ([@B29]). These results suggest that ectopic ORs expressed in non-nasal tissues can play a role in functional GPCR proteins and stimulate unique signal transduction pathways, resulting in tissue-specific roles by recognizing odorants as ligand molecules.

Skeletal muscle is a major organ of ATP consumption, which is critical for sustaining oxidative metabolism and homeostasis of the ATP pool in healthy individuals ([@B48]). Under intensive exercise, nearly 90% of cardiac output is distributed to skeletal muscle. Regulating the energy metabolism of skeletal muscle is critical to maintain normal physiology. It has been shown that energy metabolism of the skeletal muscle is largely regulated by mitochondrial function and a balance between mitochondrial biogenesis and the autophagy pathway ([@B48]). Enrichment of mitochondria in skeletal muscle improves oxygen uptake capacity and reduces adipose tissue mass, thus increasing exercise capacity and lowering the risk of type 2 diabetes and cardiovascular disease ([@B35]; [@B7]; [@B48]).

Mitochondrial contents in skeletal muscle can be stimulated by mitochondrial biogenesis ([@B64]; [@B44]), which is regulated by multiple signaling pathways, including peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α). PGC-1α is stimulated by several kinases, including CREB and extracellular signal-regulated protein kinases 1/2 (ERK1/2). PGC-1α is also activated through deacetylation by the NAD-dependent protein deacetylase sirtuin-1 (SIRT1) ([@B13]; [@B59]; [@B39]). PGC-1α activation induces downstream transcription factors, such as nuclear respiratory factors (NRF1 and NRF2) and mitochondrial transcription factor A (TFAM), which upregulate genes encoding mitochondrial biogenesis and electron transport chain proteins ([@B63]; [@B48]). Thus, PGC-1α is well involved in mitochondrial biogenesis and function ([@B50]; [@B49]).

AzA is a C9 α,ω-dicarboxylic acid (nonanedioic acid) that is found in grain foods, including oatmeal and barley ([@B12]), and is also endogenously produced by the peroxisomal ω-oxidation pathway as an end product of linoleic acid ([@B36]). AzA is a ligand for the mouse olfactory receptor Olfr544 ([@B29]; [@B60]); thus, oral administration of AzA in mice reduces adiposity, rewiring fuel preference to fats ([@B60]). Our microarray analysis of mouse skeletal muscle tissues identified Olfr544 as the most highly expressed OR. Therefore, we further investigated the biological function of AzA on mitochondrial biogenesis in skeletal muscle cells both *in vitro* and *in vivo*. Moreover, the molecular mechanism of Olfr544-mediated mitochondrial biogenesis in the muscle was also examined in both wild-type and Olfr544-deficient mice.

Materials and Methods {#S2}
=====================

Cell Culture, Differentiation, and Compound Treatment {#S2.SS1}
-----------------------------------------------------

The C2C12 cells (American Type Culture Collection, United States) were cultured in Dulbecco's modified Eagle medium (DMEM, Gibco, MA, United States) containing with 20% fetal bovine serum (FBS, HyClone, IL, United States), 100 units/mL of penicillin and 100 mg/mL streptomycin (PEST, Sigma-Aldrich, St. Louis, MO, United States) at 37°C with 5% CO~2~ (v/v). The cells were differentiated as previously described ([@B54]). Briefly, mouse skeletal muscle C2C12 cells were switched to DMEM containing 2% horse serum (HyClone). After a 7-day differentiation, cells were treated with AzA (Sigma) in serum-free DMEM for 24 h. DMSO (0.1%, Bio Basic Canada Inc., Canada) was used as a control.

Double-Transfection of Small Interfering RNA (siRNA) {#S2.SS2}
----------------------------------------------------

C2C12 cells were seeded overnight and differentiated for 7 days. Differentiated skeletal myotubes were transfected with 200 pmol of scramble or *Olfr544* siRNA duplex (SantaCruz, CA, United States) with Lipofectamine 2000 reagent (Invitrogen, CA, United States) as previously described ([@B62]). After transfection for 6 h, differentiated skeletal myotubes were transfected again with the same amount of scramble or *Olfr544* siRNA. After 5 h of double transfection, cells were added with fresh DMEM containing 20% FBS. Subsequently, transfected cells were treated for 10h with DMSO or AzA before total mRNA or protein extraction.

Quantitative Real-Time RT-PCR {#S2.SS3}
-----------------------------

The reagent of RNAiso Plus (TaKaRa Bio Inc., Otsu, Japan) was used to extract the total RNA of C2C12 cells and muscle tissues. Subsequently, Rever Trace RT Master Mix Kit (Toyobo, Osaka, Japan) was used to synthesize the cDNA according to the manufacturer's instructions using the. Quantitative RT-PCR experiments were then conducted to check the gene expression levels with cDNA as previously described ([@B25]; [@B29]; [@B62]). Templates were amplified by using specific sets of primers listed in [Supplementary Table S1](#SM1){ref-type="supplementary-material"} with the Thunderbird^TM^ SYBR qPCR Mix reagent (Takara Bio Inc., Japan) and analyzed by the iQ5 Cycler System (Bio-Rad, Hercules, CA, United States). *Olfr544* mRNA levels was quantified in reference to pME18S-Olfr544 plasmid and normalized to ribosomal protein L32 levels.

Immunoblotting Analysis {#S2.SS4}
-----------------------

Immunoblotting analysis was used to measure the protein levels of C2C12 and muscle tissues ([@B28]; [@B22]; [@B27]). Briefly, lysates of skeletal muscle cells and tissues were obtained in a radioimmunoprecipitation assay buffer containing protease and phosphatase inhibitors (Thermo, Waltham, MA, United States). The protein levels were checked using protein assay dye reagent (Bio-Rad, Hercules, CA, United States). Subsequently, SDS-PAGE were used to separate the denatured proteins. The separated proteins were then transferred to the nitrocellulose membranes (Daeillab, Seoul, South Korea). The membranes were incubated overnight with primary antibodies at 4°C. Antibodies for CREB (1:250), p-CREB (Ser133; 1:500), β-actin (1:1000), α-tubulin (1:1000), ERK1/2 (1:500), p-ERK1/2 (Thr53/54, 1:500), PGC-1α (1:500) were purchased from Santa Cruz Biotechnology (United States); anti-LC3B (1:500) from Novus Biologicals (Novus Biologicals, Littleton, CO, United States). Immunoblotting images were accessed by a ChemiDoc^TM^ touch imaging system, and analyzed by the Image Lab 5.2 software (Bio-Rad, PA, United States). The protein levels of α-tubulin or β-actin were used for normalization.

Mitochondrial DNA Content and Abundance Determination {#S2.SS5}
-----------------------------------------------------

Mitochondrial DNA content and abundance were determined as previously described ([@B54]). Mitotracker Green probe (Molecular Probes) was used to measure the mitochondrial density following the manufacturer's instructions. Briefly, C2C12 cells were stained with Green probes (200 nm) for 30 min at 37°C after washing with PBS (pH 7.4). Subsequently, the green fluorescence intensity was measured using SpectraMAX (Molecular Devices Co.), at the wavelength of 490 nm (excitation) and 516 nm (emission), respectively. The images were obtained by the Zeiss LSM700 confocal microscope, and then analyzed using the Zeiss LSM700 version 3.2 software (Carl Zeiss, Germany).

Mouse Care and Experiments {#S2.SS6}
--------------------------

Healthy, male, 8-week-old ICR, and C57BL/6J mice weighing 20--25 g were purchased from Samtako (Gyeonggi-do, South Korea). Generations of Olfr544 knockout mice were generated using the CRISPR/Cas9 system to delete exon 2 (161--428 bp) of the O*lfr*544 gene, and the method and basic characteristics of Olfr544 knockout mice (KO) were previously published ([@B60]). Animal experiments were handled in accordance with the protocols approved by the Animal Experiment Committee of Korea University (Protocol No. KUIACUC-2019-0031). Animals were kept in the animal room with a 12 h photoperiod and a relative humidity of 50--60% at 21--25°C. Mice were allowed free access to 60% high fat diet (HFD) and randomly assigned into four groups (*n* = 7), two groups each for wild-type and Olfr544 knockout mice. For acute Olfr544 activation, mice were fasted overnight and intraperitoneally injected with either AzA (100 mg/kg body weight) or PBS (vehicle group). Skeletal muscle tissues (soleus muscles) were collected at indicated time as previously described ([@B26]). For long-term AzA administration, mice were orally administered either AzA (50 mg/kg body weight) or ddH~2~O under HFD. The body weights of mice were recorded every week. After oral feeding for 6 weeks, mice were anesthetized and sacrificed after overnight fasting. Muscle tissues were collected, immediately cryoprotected, and then stored at --80°C for further experiments.

Statistical Analysis {#S2.SS7}
--------------------

The data are shown as the means ± SEM. To determine significance between two or multiple groups, Wilcoxon test and one-way ANOVA followed by Tukey's HSD test were used, respectively. Data are statistically significant different denoted by ^∗^ for *P* ≤ 0.05, ^∗∗^ for *P* ≤ 0.01.

Results {#S3}
=======

Olfr544 Is Expressed in Cultured C2C12 Derived Myotubes, and Its Activation Induces the PKA-CREB-PGC-1α Signaling Axis {#S3.SS1}
----------------------------------------------------------------------------------------------------------------------

In a microarray analysis of mice fed normal CHOW and high-fat diet (HFD), Olfr544 was the most highly expressed OR in skeletal muscles. The expression levels of Olfr544 were not significantly changed by HFD ([Supplementary Methods](#SM2){ref-type="supplementary-material"} and [Supplementary Figure S1](#SM1){ref-type="supplementary-material"}). The expression of Olfr544 was further confirmed in differentiated C2C12 myotubes and mouse skeletal muscle tissues using RT-PCR ([Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}). Olfr545, which shares 95% sequence homology with Olfr544, was also expressed at low levels, with approximately 20% of Olfr544 expression ([Supplementary Figure S2A](#SM1){ref-type="supplementary-material"}). In the CRE-luciferase reporter gene assay, AzA, a ligand of Olfr544, weakly activated Olfr545; thus, the EC50 value of AzA for Olfr545 was 12-fold greater than that of Olfr544 (EC50; 19.2 ± 4.8 vs. 237 ± 140 μM for Olfr544 and Olfr545, respectively, [Supplementary Figures S2B,C](#SM1){ref-type="supplementary-material"}). Further experiments were performed with AzA concentrations to selectively stimulate Olfr544 but not Olfr545.

In cultured C2C12 myotubes, AzA stimulated the PKA-CREB signaling axis ([Supplementary Figure S2B](#SM1){ref-type="supplementary-material"}), in line with the results from the CRE-luciferase assay ([Supplementary Figure S2C](#SM1){ref-type="supplementary-material"}). AzA induced pCREB levels by 1.5-fold in C2C12 myotubes; meanwhile, the induction of pCREB was abrogated in cells with Olfr544 knockdown ([Figures 1A,B](#F1){ref-type="fig"}). The expression of Olfr544 in cultured Olfr544 knockdown myotubes was silenced by 80% with transfection of Olfr544 specific siRNA ([Supplementary Figure S3](#SM1){ref-type="supplementary-material"}). When differentiated C2C12 myotubes were stimulated with AzA (0--50 μM), the mRNA and protein expressions of PGC-1α in myotubes were induced a dose-dependent manner. AzA (50 μM) significantly induced the mRNA and protein expression levels of PGC-1α, by 2- and 3-fold, respectively ([Figures 1C,D](#F1){ref-type="fig"}). However, these inductions were negated in Olfr544 knockdown cells ([Figures 1E,F](#F1){ref-type="fig"}). We did not observe the significant difference of mRNA *Pgc-1*α expression stimulated by AzA in cells transfected with scramble or Olfr544 siRNA (*P* = 0.125). Nonetheless, we further confirmed that the PGC-1α protein expression was induced by AzA treatment in the presence of scramble siRNA and significantly higher the expression level in the presence of Olfr544 siRNA ([Figure 1F](#F1){ref-type="fig"}). These data demonstrate that Olfr544 activation stimulates the CREB-PGC-1α signaling axis in cultured myotubes.

![Activation of Olfr544 induces the PKA-CREB-PGC-1α signaling axis in cultured skeletal muscle cells. **(A,B)** AzA induced pCREB expression in C2C12 myotubes but not in cells with Olfr544 knockdown. Immunoblotting analysis of pCREB and total CREB proteins (A, *n* = 3); the ratios of pCREB-to-CREB were normalized to β-actin (**B**, *n* = 3). **(C,D)** AzA induced the expression of PGC-1α both at the mRNA (**C**, *n* = 3) and protein levels (**D**, *n* = 3) in a dose-dependent manner as measured by real-time qPCR and immunoblotting, respectively. **(E,F)** Olfr544 gene knockdown lessens Pgc-1α gene expression (**E**, *n* = 3) and protein expression (**F**, *n* = 3). Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g001){#F1}

AzA Induces Mitochondrial Biogenesis in Cultured C2C12 Derived Myotubes {#S3.SS2}
-----------------------------------------------------------------------

We next investigated whether AzA stimulates mitochondrial biogenesis in C2C12 derived myotubes since the CREB-PGC-1α signaling axis has been reported to activate mitochondrial biogenesis ([@B20]; [@B50]). C2C12 cells were differentiated for 7 days and then treated with AzA for 24 h. Quantitative real-time PCR results showed that 50 μM AzA significantly increased the mtDNA content by 3.0-fold ([Figure 2A](#F2){ref-type="fig"}). Similarly, mitochondrial density was significantly increased by approximately 2.5-fold ([Figure 2B](#F2){ref-type="fig"}). Subsequently, MitoTracker-probed mitochondrial images observed under confocal fluorescence microscopy showed substantial increases in mitochondrial density ([Figure 2C](#F2){ref-type="fig"}). These results suggest that AzA induces mitochondrial biogenesis in skeletal muscle cells.

![AzA induces mitochondrial biogenesis in skeletal muscle cells. **(A)** AzA induces mtDNA content in a dose-dependent manner as measured by Qpcr (*n* = 4). **(B)** Mitochondrial contents were probed by green MitoTracker and measured by a spectrophotometer (*n* = 4). **(C)** and the levels of mitochondrial content was confirmed under confocal fluorescence microscopy (*n* = 3). Blue, nucleus; green, mitochondrion. Scale bar, 50 μm. Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g002){#F2}

Olfr544 Gene Knockdown Negates Mitochondrial Biogenesis Stimulated by AzA in Cultured C2C12 Derived Myotubes {#S3.SS3}
------------------------------------------------------------------------------------------------------------

We next examined whether AzA regulates mitochondrial biogenesis via Olfr544 activation. C2C12 cells were transfected with scramble siRNA or Olfr544 siRNA after differentiation, and then treated with AzA for 24 h. Olfr544 knockdown negated the effect of AzA on mitochondrial biogenesis. The mtDNA content and mitochondria abundance were unaltered by AzA stimulation in Olfr544 knockdown cells ([Figures 3A,B](#F3){ref-type="fig"}). In contrast, AzA-treated control C2C12 myotubes showed a significant induction of mtDNA content by 2.0-fold compared with controls. AzA treatment increased mtDNA content in normal cells by approximately 1.6-fold compared with Olfr544 knockdown cells ([Figure 3A](#F3){ref-type="fig"}). Quantification of mitochondrial density showed the enrichment of mitochondria in cells stimulated with AzA (50 μM) in C2C12, but not in Olfr544 knockdown C2C12 myotubes ([Figures 3B,C](#F3){ref-type="fig"}). However, the effects of AzA on mitochondrial biogenesis were impaired with siRNA transfection, which was smaller ([Figure 3](#F3){ref-type="fig"}) than the effects in non-transfected cells ([Figure 2](#F2){ref-type="fig"}). The results collectively demonstrate that AzA stimulates muscle mitochondrial function via Olfr544 activation.

![Olfr544 deficiency negates mitochondrial biogenesis stimulated by AzA in skeletal muscle cells. **(A)** AzA induced mtDNA content in myotubes but not in Olfr544 knockdown cells (*n* = 8). Mitochondrial abundance was analyzed using a spectrophotometer (**B**, *n* = 8) and fluorescence imaging (**C**, *n* = 3). Scale bar, 50 μm. Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05, \*\* for *P* ≤ 0.01 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g003){#F3}

Olfr544 Activation Induces ERK1/2 Phosphorylation in Cultured C2C12 Derived Myotubes {#S3.SS4}
------------------------------------------------------------------------------------

PGC-1α gene expression is alternatively induced by ERK1/2; thus, we next checked the phosphorylation level of ERK1/2 by AzA in differentiated C2C12 myotubes. In immunoblotting analysis, AzA significantly induced phosphorylations of ERK1/2 on Thr43/44 (pERK1/2) by 2.0-fold, but these effects were abrogated in Olfr544 knockdown cells ([Figures 4A,B](#F4){ref-type="fig"}). It has been reported that increased pERK1/2 correlates to autophagy levels ([@B38]). Autophagy plays a pivotal role in skeletal muscle adaption and capacity by interacting with mitochondrial biogenesis and preventing mitochondrial damage ([@B19]; [@B34]; [@B37]). In cultured C2C12 myotubes, activation of Olfr544 by AzA increased the LC3-II-to-LC3-I ratio, a marker of autophagosome formation, by 2.5-fold compared to vehicle-treated controls, while the induction disappeared in Olfr544 knockdown cells ([Figures 4C,D](#F4){ref-type="fig"}). Importantly, AzA-stimulated cells showed an approximately 3.0-fold increase of the LC3-II-to-LC3-I ratio compared to the Olfr544 knockdown cells ([Figure 4D](#F4){ref-type="fig"}). Taken together, Olfr544 activated by AzA increases ERK1/2 activity and induces autophagy formation in skeletal muscle cells.

![AzA-driven Olfr544 activation stimulates ERK1/2 phosphorylation in cultured skeletal muscle cells. AzA induced phosphorylation of ERK1/2 on Thr43/44 (pERK1/2) in myotubes but not in Olfr544 knockdown cells. **(A,B)** Expression of total ERK1/2 and pERK1/2 was probed by immunoblotting. Ratios of pERK1/2 to total ERK1/2 were normalized to β-actin (*n* = 3). **(C,D)** AzA-stimulated myotubes increased the LC3-II-to-LC3-I ratio, a marker of autophagosome formation, but not in Olfr544 knockdown cells (*n* = 3). Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05, \*\* for *P* ≤ 0.01 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g004){#F4}

Olfr544 Activation Stimulates the CREB-PGC-1α Pathway and Autophagy Formation in Mouse Skeletal Muscle Tissues {#S3.SS5}
--------------------------------------------------------------------------------------------------------------

We next investigated the biological activities of AzA in mouse skeletal muscle tissues *in vivo*. Mice were intraperitoneal injected with AzA (100 mg/kg body weight) for 30 or 120 min before soleus muscles collection for immunoblot analysis. Vehicle group mice were injected with PBS for 30 or 120 min. The results demonstrated that AzA stimulated pCREB by 2-fold after a 2 h injection of AzA ([Figures 5A,B](#F5){ref-type="fig"}). The expression of PGC-1α upon AzA treatment was also upregulated by approximately 1.5-fold in soleus muscle tissues ([Figures 5A,C](#F5){ref-type="fig"}). However, the expressions of pCREB and PGC-1α were unaffected in skeletal muscle tissues of Olfr544-deficient mice ([Figures 5B,C](#F5){ref-type="fig"}). These results demonstrated that AzA might regulate mitochondrial biogenesis in skeletal muscle tissues through activation of the Olfr544-CREB-PGC-1α signaling axis.

![AzA-driven Olfr544 activation stimulates the CREB-PGC-1α signaling axis and autophagy formation in mouse skeletal muscle tissues. **(A)** AzA treatment induced the expression of PGC-1α, pCREB, pERK1/2 and LC3I/II protein in wild-type mouse skeletal muscle tissues but not in those of Olfr544 KO mice. Immunoblotting analysis of soleus muscles extracts for PGC-1α, pCREB, and CREB, pERK1/2 and total ERK1/2, LC3I/II (*n* = 3). **(B--E)** Ratios of pCREB, PGC-1α, pERK1/2, and LC3-II were normalized to β-actin (*n* = 3). Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g005){#F5}

Additionally, the levels of pERK and the pERK-to-ERK ratio were also significantly increased by 3.0-fold in soleus muscle tissues after 30 min of AzA treatment ([Figures 5A,D](#F5){ref-type="fig"}). The LC3-II-to-LC3-I protein expression ratio was increased by 1.5-fold after 30 min of AzA; however, these inductions were negated in the skeletal muscle of Olfr544 knockout mice ([Figures 5A,E](#F5){ref-type="fig"}). These suggest that AzA-dependent Olfr544 activation in skeletal muscle tissues induces mitochondrial biogenesis by activation of CREB-PGC-1α and stimulates autophagy formation.

Oral Administration of AzA Activates Mitochondrial Biogenesis in HFD-Induced Obese Mice {#S3.SS6}
---------------------------------------------------------------------------------------

Finally, we investigated metabolic effect of AzA administration on skeletal muscle tissue in HFD-induced obese mice. Obesity is inversely associated with mitochondrial replication and skeletal muscle function, which are caused by cellular oxidative stress, lipotoxicity, and insulin resistance ([@B23]; [@B64]). Skeletal muscle in obese mice and humans increases intramuscular triglyceride concentrations while reducing the rate of lipid oxidation by impairing mitochondrial enzymes ([@B13]; [@B23]).

Both wild-type and Olfr544 knockout mice were fed HFD to induce obesity and were then orally administered AzA (50 mg/kg body weight/day) for 6 weeks. Body weight and plasma glucose and triglyceride concentrations were reduced and glucose tolerance improved by AzA administration in wild-type mice but not in Olfr544 knockout mice, as reported previously ([@B60]). The mRNA expression of PGC-1α was induced by 2.0-fold in AzA soleus muscles compared with those in control mice. In contrast, the induction was abrogated in Olfr544 knockout mice ([Figure 6A](#F6){ref-type="fig"}). Herein, we got the significant difference of PGC-1α mRNA expression between AzA-administrating WT mice compared to vehicle mice. We also observed the reduced trend in AzA-administrating Olfr544 KO mice compared to that of WT mice ([Figure 6A](#F6){ref-type="fig"}) although *p* = 0.07. Similarly, expression of the downstream transcriptional target of PGC-1α, mitochondria transcription factor A (*Tfam*), which indicates mitochondrial replication and function, was substantially induced by 3.0-fold in AzA administered wild-type mice, whereas these inductions were negated in skeletal muscles of Olfr544 knockout mice ([Figure 6B](#F6){ref-type="fig"}). The mtDNA content of AzA-administered wild-type skeletal muscle significantly increased by approximately 3.0- and 2.0-fold compared with vehicle-treated wild-type and AzA-administered Olfr544 knockout skeletal muscle, respectively ([Figure 6C](#F6){ref-type="fig"}). In contrast, the mtDNA content was not altered by AzA administration in Olfr544 knockout mice ([Figure 6C](#F6){ref-type="fig"}). Collectively, these data demonstrate that AzA stimulates mitochondrial biogenesis and mitochondrial contents in skeletal muscle tissues via activation of Olfr544 ([Figure 6D](#F6){ref-type="fig"}).

![Oral administration of AzA activates mitochondrial biogenesis in skeletal muscle tissues in HFD-induced obese mice. **(A)** AzA induced Pgc-1α gene expression in wild-type mouse skeletal muscle tissues but not in those of Olfr544 KO mice (*n* = 4). **(B,C)** Gene expression of the mitochondrial marker Tfam and mtDNA content were measured by real-time qPCR (*n* = 4). **(D)** Schematic illustration proposing the mechanism by which AzA-driven Olfr544 activation induces mitochondrial biogenesis in skeletal muscle cells by stimulation of CREB-PGC-1α signaling and ERK1/2 activity. Data are the mean ± SEM. Data are statistically significant different denoted by \* for *P* ≤ 0.05 using Wilcoxon test and one-way ANOVA followed by Tukey's HSD test.](fphys-11-00329-g006){#F6}

Discussion {#S4}
==========

Mitochondrial dysfunction has been suggested to be causally involved in obesity-induced insulin resistance and in the pathophysiology of type II diabetes (T2D). This raised the possibility that mitochondria in skeletal muscle cells could be targets to prevent type 2 diabetes mellitus ([@B15]; [@B21]), and these biological processes can be regulated by natural substances and food molecules.

AzA s contained in several grain food (oat, barley, etc.) and can be endogenously synthesized by ω-oxidation process as an end product of linoleic acid. Thus, we believe that Olfr544 in extra-nasal tissues such as skeletal muscle can be endogenously stimulated by AzA derived from diet or endogenous synthesis. In our previous studies, AzA levels were particularly increased in fasting state compared with those in fed state ([@B60]), thus we suggested that AzA is a redundant fasting signaling molecule that can activate Olfr544 in multiple tissue. Previously we reported that Olfr544 activation by AzA induces white adipose lipolysis, brown adipose thermogenesis, and hepatic fatty acid oxidation ([@B60]). In this study, we found additional function of Olfr5444, the activation of mitochondrial biogenesis in skeletal muscle. AzA has been detected in humans ([@B1]) and AzA treated human adipose cells showed induced lipolysis, suggesting that AzA has similar functions in humans as well. Biological effects of AzA have been reported. Toxicity studies of AzA have been reported *in vivo*, and the oral LD50 in rats is \> 5 g/Kg (Thermo Fisher, MSDS). Pharmacokinetic studies revealed that, in the case of oral administration, approximately 60% of the systemically absorbed AzA is eliminated unchanged through the kidneys. After an intravenous dose, approximately 80% is excreted in the urine within 12 h of administration ([@B14]; [@B51]). In healthy humans, plasma AzA can reach up to 75 mg/L after 2 h of oral administration of 0.5--5 g ([@B11]).

Several physiological effects of AzA have been reported. AzA promotes the reduction of lipid peroxides into lipid hydroxides, preventing cardiovascular diseases ([@B46]). Animal feeding studies have reported that AzA can reduce atherosclerosis and diabetes phenotypes with the reduction of plasma triglycerides and glucose concentrations and the improvement of glucose tolerance. AzA has been reported to ameliorate glucose metabolism and cholesterol plaque formation in the arteries when administered orally ([@B41]). AzA administration reduced plasma glucose, insulin, liver glycogen and key carbohydrate metabolic enzymes in HFD-induced type 2 diabetic mice ([@B36]; [@B41]). These data suggest that AzA may have preventive and therapeutic potential for the treatment of obesity-induced T2DM. We have also reported that activation of Olfr544 by AzA stimulates fatty acid oxidation in hepatocytes and brown adipose tissue, resulting in the reduction of adiposity and the rewiring of fuel preferences toward fats in obese mice ([@B60]). These findings suggest that Olfr544 can respond to AzA and stimulate cellular energy metabolism under physiological pathways in a variety of tissue types, especially skeletal muscle.

Olfactory receptor signaling pathways and their downstream molecular effectors may serve as effective pharmacologic targets for improving both muscle physiology and the efficiency of cells ([@B24]; [@B17]). In the present study, we demonstrate that Olfr544-dependent PGC-1α and ERK1/2 stimulation is involved in skeletal muscle mitochondria in response to AzA stimulation *in vitro* and by oral administration in skeletal muscle tissues. To the best of our knowledge, this is the first report of ectopic functional expression of ORs on mitochondrial biogenesis in skeletal muscle. Olfr544 activation by AzA induced both mitochondrial biogenesis and autophagy via ERK-LC3II activation. This autophagy can stimulate mitochondrial biogenesis coupled with the removal of damaged and unhealthy mitochondria ([@B31]).

Mitochondrial biogenesis can be induced by exercise training or exercise mimetics via activation of PGC-1α ([@B42]; [@B45]; [@B58]). Activated PGC-1α regulates gene expression, encoding proteins related to mitochondrial biogenesis, oxidative respiration in muscle fibers, and exercise-induced autophagy ([@B63]; [@B18]; [@B34]). Moreover, PGC-1α expression can induce gene expression of an insulin-sensitive glucose transporter that enhances glucose uptake in skeletal muscle cells ([@B40]). Meanwhile, autophagy is involved in the turnover of mitochondria and other cellular organelles ([@B56]). Autophagy results in enhanced oxidative metabolism in muscle and is required for endurance exercise training-induced skeletal muscle adaption by mitochondrial biogenesis induction, which improves physical performance ([@B34]). Therefore, the enhancement of mitochondrial biogenesis and autophagy in muscle can increase skeletal and brown fat mass that consequently increases energy expenditure and reduces diet-induced obesity.

ERKs regulate both mitochondrial biogenesis and autophagy ([@B52]; [@B8]; [@B4]; [@B57]). The localization of phosphorylated ERK2 to the mitochondria is tightly correlated with autophagic/mitophagic cell stress ([@B6]). It has been shown that several GPCR proteins including olfactory receptors stimulate ERK phosphorylation by β-arrestin-dependent manners ([@B2]; [@B9]).

Activation of ERK1/2 subsequently triggers phosphorylation of a number of downstream targets that regulate the autophagy pathway. ERK1/2 phosphorylation has been shown to enhance autophagy in Silymarin-treated Beas-2B cells or mediate phosphorylated Bcl-2 regulated starvation-induced autophagy ([@B53]; [@B33]). It has been shown that MEK-ERK inhibitors, such as U0126, or amino acids can inhibit autophagy ([@B43]; [@B53]). Several recent studies have reported that ERK-mTOR signaling may play a major role in autophagy regulation. It has been suggested that transiently or moderately activated ERK1/2 inhibits mTOR activity, which improves cytoprotective autophagy ([@B55]). Recently, [@B38], revealed that ERK1/2 phosphorylation could be used to determine the cellular availability of autophagic structures because LC3 II-positive membranes in pre-autophagosomes might promote coordination of the MEK-ERK1/2 signaling cascade. Here, we observed that AzA-driven Olfr544 activation increased ERK1/2 activity both *in vitro* and *in vivo* followed by the partial induction of LC3-II-to-LC3-I conversion, a marker of autophagy. However, the ratio LC3-II-to-LC3-I were decreased in mice with acute AzA injection for 120 min, indicating alternative pathways may be involved in the regulation of AzA on autophagy. Nonetheless, the detailed mechanism by which AzA-activated Olfr544 induces autophagy in skeletal muscle is required for further studies.

In this study, we investigated acute effect of Olfr544 activation by AzA in both wild-type and Olfr544 KO mice and there was no HFD group ([Figure 5](#F5){ref-type="fig"}). We also administered AzA orally in HFD fed wild-type and Olfr544 KO mice and there was no chow diet group ([Figure 6](#F6){ref-type="fig"}). It should have been better to include both chow and HFD groups in studies of [Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, however, our major interest in experiments in [Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"} were to examine the effect of Olfr544 activation but not to find the effect of HFD. However, the comparison between normal chow and HFD has been investigated by other researchers. It has been reported that HFD affects expression of genes involved in mitochondrial function and biogenesis ([@B30]; [@B5]). ERK levels and the LC3-II/I ratios are induced in HFD-fed skeletal muscle ([@B5]). Moreover, a 90 and 40% reduction in mRNA and protein levels, respectively, were observed for Pgc1α after 3-week HFD ([@B30]).

Skeletal muscle mitochondria are required for muscle physical performance and are beneficial for treating obesity and obesity-induced T2D owing to their lipid oxidation and glycolytic energy capacities ([@B47]; [@B16]; [@B21]). Our findings demonstrate a novel function of olfactory receptor Olfr544 in skeletal muscle mitochondrial homeostasis. Olfr544 activation contributions to mitochondria biogenesis via PKA-CREB-PGC-1α and ERK-LC3II signaling ([Figure 6D](#F6){ref-type="fig"}) in skeletal muscle. These data also suggest that Olfr544 may be a potential target to stimulate skeletal muscle function.
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